Hexahydro-1H-4,7-methanoisoindole-1,3-dione compounds
View Patent ↗The present invention is directed to therapeutic agents which are atypical antipsychotics and which are useful in the treatment of neurological and psychiatric disorders associated with dopamine D2 and serotonin 5-HT2A neurotransmission dysfunction.
1. A compound which is:
or a pharmaceutically acceptable salt thereof.
2. A compound which is:
3. A compound which is:
in the form of a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound of claim 1 or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound of claim 2 .
6. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and the compound of claim 3 in the form of a pharmaceutically acceptable salt thereof.
7. A method for treating schizophrenia in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
8. A method for treating schizophrenia in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 2 .
9. A method for treating schizophrenia in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 3 in the form of a pharmaceutically acceptable salt thereof.
10. A method for treating bipolar disorder in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
11. A method for treating bipolar disorder in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 2 .
12. A method for treating bipolar disorder in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 3 in the form of a pharmaceutically acceptable salt thereof.
13. A method for treating anxiety in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
14. A method for treating anxiety in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 2 .
15. A method for treating anxiety in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of the compound of claim 3 in the form of a pharmaceutically acceptable salt thereof.